CLINICAL AND HUMAN TESTING

Similar documents
BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.

All diseases on Foresight

CHRONIC MYELOGENOUS LEUKEMIA

CarrierMap. Genetic Counseling. Technology TABLE OF. Sample Report CONTENTS. New Offerings. Recombine Facts. Disease List

Foresight Carrier Screen

Foresight Carrier Screen

Foresight Carrier Screen

Foresight Carrier Screen

23andMe Reports GENETIC HEALTH RISK REPORTS. Increased risk for breast and ovarian cancer. function

Foresight Carrier Screen

PATIENT EDUCATION. carrier screening INFORMATION

NutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:

Foresight Carrier Screen

High Impact Treatment Benefits X-Linked Moderate Impact. Disease Gene # Mutations Disease Group(s)

CARRIER SCREEN - LIST OF DISORDERS

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

Foresight Carrier Screen

Family Prep Screen POSITIVE: HIGH REPRODUCTIVE RISK. Cystic Fibrosis

Further expansion of the neonatal screening panel in the Netherlands

Should Universal Carrier Screening be Universal?

JOHN DOE JANE DOE. Reproductive Risk Summary. Counsyl Test Results Summary

Residual risks by ethnicity

The Israeli population carrier screening program. Joël Zlotogora MD, PhD Hadassah medical school Hebrew University Jerusalem

The Counsyl Foresight Carrier Screen

HERES Carrier Screening TEST

Newborn Screening: Focus on Treatment

Summary of Results CARRIER STATUS DNA INSIGHT. Result: Carrier, Heterozygote. Protected Health Information. Propionic Acidemia

Expanded Carrier Screening: What s Best?

Evolve FamilyReady Carrier Screen

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.

ORIGINAL RESEARCH ARTICLE

Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy

SAMPLE. Carrier Screening Results Report v2.2 Page 1/8

For Your Baby s Health Department of Health

A. disorders of amino acid metabolism classical phenylketonuria and hyperphenylalaninemia

[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995

PREDICAGEN LLC REPORT

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert

When users open the application interface, the starting page presents a disclaimer. Upon agreeing to the

Related Policies None

Diagnose a broad range of metabolic disorders with a single test, Global MAPS

COMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS

Results Recipient Ordering Healthcare Professional Male Details Female Details

Positive Newborn Screens: What do you do next?

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION

Sperm Donor Profile. Asian American Indian African American/Black. Caucasian/White East Indian Latino/Hispanic

(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;

QUESTION. Personal Behavior History. Donor Genetic History. Donor Medical History. Family Medical History PERSONAL BEHAVIOR HISTORY. Never N/A.

23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert

Metabolic Disorders Screened Overseas but not Screened in Australia Condition Features Inherited Diagnosis Treatment Newborn Screen

Carrier Screening for Genetic Diseases

HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up

Table S5. Disease pairs that have a significant comorbidity and are connected in either KEGG or BiGG database

Expanded carrier screening for monogenic disorders: where are we now?

A Guide for Prenatal Educators

Preconceptional Test For Monogenic Diseases

Most common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.

Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015

Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

General Approach to Genetic Testing

Beyond the case for NBS in South Africa. Chris Vorster 28/05/2016

Corporate Medical Policy

Medical Policy Preimplantation Genetic Testing

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

NEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School

Standard Therapies - Cord Blood

Title: Assessing Recommendations Related To Timeliness of Newborn Screening

disease carrier status PANEL DETAILS VERSION Risk Details JANE MILLER JOHN MILLER NEGATIVE CARRIER * NEGATIVE MILD CONDITION NEGATIVE

PGD: A Celebration of 20 years:

Newborn Screening: Blood Spot Disorders

NEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

רשימת המחלות הנסקרות בבדיקה

BULGARIAN NATIONAL PLAN. Associate professor Alexey Savov PhD National Consulting Council for Rare Diseases (NCCRD)

Archived Reports Summary

Utility of Microarrays in Molecular Genetics

The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot

BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.

Survey of prenatal testing for genetic disorders in Japan: Recent report

Newborn Screening in Manitoba. Information for Health Care Providers

Considerations in Choosing Screening Conditions: One (US) Approach

CARRIER SCREENING PANEL

Approach to diagnosis of metabolic diseases

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Beyond Mendel s Laws of Inheritance

Our partners worldwide. CENTOGENE Report: Diagnosed cases of rare diseases at CENTOGENE. January 2012 to June 2016.

Original Policy Date

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

Knowledge is power. Plan ahead with GeneAware.

genetic carrier screening for cystic fibrosis results you Can trust

Metabolic Changes in ASD. Norma J. Arciniegas, MD Simón E. Carlo, MD Instituto Filius

NEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School

NEWBORN METABOLIC SCREEN, MINNESOTA

Expanded carrier screening in an infertile population: how often is clinical decision making affected?

Newborn Screening in Washington State Saving lives with a simple blood spot

Sema4 Natalis. Clinical significance of panel. Testing methods, sensitivity, and limitations

Family Medical History Questionnaire (FMHQ)

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM

TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN

What s New in Newborn Screening?

Transcription:

CLINICAL AND HUMAN TESTING CARRIER SCREENING FOR FAMILY PLANNING Let knowledge be your guide. Identify genetic conditions before or during a pregnancy to help predict the chances of having a child with a genetic disorder.

HerediT CF Highly accurate carrier screen for clinically relevant cystic fibrosis mutations. A direct answer about a common genetic disorder. For couples considering having a child or those with a family history of cystic fibrosis, male infertility or for whom an ultrasound has indicated an increased risk for cystic fibrosis, the HerediT Cystic Fibrosis Carrier Screening laboratory-developed test provides highly accurate results on clinically relevant mutations. TEST PERFORMANCE DATA The HerediT Cystic Fibrosis carrier screening test includes the most comprehensive number of disease-causing mutations available (136 mutations). The performance characteristics of the HerediT CF test have been analytically validated using CFTR gene mutations shown to be phenotypically relevant.1,2,3. ETHNICITY DETECTION RATE POPULATION RISK RESIDUAL RISK AFTER A NEGATIVE SCREEN Caucaisan Ashkenazi 93% 1/25 1/344 Jewish 95% 1/24 1/461 Hispanic 82% 1/58 1/318 African American 76% 1/61 1/251 Asian 76% 1/25 1/208 1: Clinical and functional translation of CFTR. US CF Foundation, Johns Hopkins University, The Hospital for Sick Children Web site. http://www.cftr2.org. Accessed Oct 4, 2012. 2: Update on Carrier Screening for Cystic Fibrosis, ACOG Committee Opinion No. 486. Obstet Gynecol. 2011;117(4):1028-1031. 3: Paladino T, et al. Comprehensive Cystic Fibrosis Screening Panel for the Detection of Clinically Relevant Mutations. Poster session presented at: American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting; 2013 June 20-23; Phoenix, AZ. Should you test your patients? More than 10 million Americans are carriers of the CF genetic mutation from across all racial and ethnic groups. The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Genetics recommends cystic fibrosis carrier screening for all patients who are planning a pregnancy or seeking prenatal care. How is the test performed? The HerediT Cystic Fibrosis Carrier Screen test is performed on a simple blood or buccal (cheek) swab sample and results are typically reported within 20 working days.

HerediT UNIVERSAL Customizable, comprehensive carrier screening for 250+ genetic disorders. Clearly defined results. Clearly defined risks. The HerediT UNIVERSAL laboratory-developed test screens for mutations associated with more than 250 clinically relevant and impactful genetic conditions and presents categorized results to help with both interpretation and counseling. CUSTOMIZABLE TO MEET YOUR PARENT S NEEDS We offer three options for your convenience: COMPLETE PANEL The comprehensive option designed to test for mutations in over 250 genetic disorders. STANDARD PANEL Test for disorders guided by ACOG and ACMG recommendatioons. JEWISH ANCESTRY PANEL Test for over 65 conditions common in the Ashkenazi and Sephardic populations How is the test performed? The HerediT UNIVERSAL test is performed on a simple blood or buccal (cheek) swab sample and results are typically reported within 20 working days. How is the test performed? The HerediT Cystic Fibrosis Carrier Screen test is performed on a simple blood or buccal (cheek) swab sample and results are typically reported within 20 working days.

DISEASE LIST The following diseases are included in the HerediT UNIVERSAL test. *Standard panel Jewish Ancestry Panel [ACOG] = Recommended by ACOG [ACMG] = Recommended by ACMG Gene specific sequencing is available for most disorders. 11-Beta-Hydroxylase-Deficient Congenital Adrenal Hyperplasia 17-Alpha Hydroxylase 17-Beta Hydroxysteroid Dehydrogenase 3 21-Hydroxylase-Deficient Classical Congenital Adrenal Hyperplasia 21-Hydroxylase-Deficient Nonclassical Congenital Adrenal Hyperplasia 3-Beta-Hydroxysteroid Dehydrogenase 3-Methylcrotonyl-CoA Carboxylase : MCCA Related 3-Methylcrotonyl-CoA Carboxylase : MCCB Related 3-Methylglutaconic Aciduria: Type 3 3-Phosphoglycerate Dehydrogenase 5-Alpha Reductase 6-Pyruvoyl-Tetrahydropterin Synthase Abetalipoproteinemia Achromatopsia: CNGB3 Related Acrodermatitis Enteropathica Acyl-CoA Oxidase I Adenosine Deaminase Adrenoleukodystrophy: X-Linked Alkaptonuria Alpha Thalassemia [ACOG]* Alpha-1-Antitrypsin Alpha-Mannosidosis Alport Syndrome: COL4A3 Related Alport Syndrome: COL4A4 Related Alport Syndrome: X-linked Amegakaryocytic Thrombocytopenia Andermann Syndrome Androgen Insensitivity Syndrome: Complete Antley-Bixler Syndrome Argininosuccinate Lyase Aromatase ARSACS Arts Syndrome Aspartylglycosaminuria Ataxia with Vitamin E Ataxia-Telangiectasia Autosomal Recessive Polycystic Kidney Disease BBS1 Related BBS2 Related BBS10 Related BBS11 Related BBS12 Related Bare Lymphocyte Syndrome: Type II Bartter Syndrome: Type 4A Beta Thalassemia [ACOG]* Beta-Hexosaminidase Pseudodeficiency Beta-Ketothiolase Biotinidase Bloom Syndrome [ACMG]* Canavan Disease [ACOG/ACMG]* Carnitine Palmitoyltransferase IA Carnitine Palmitoyltransferase II Carpenter Syndrome Cartilage-Hair Hypoplasia Cerebrotendinous Xanthomatosis Charcot-Marie-Tooth Disease with Deafness: X-Linked: GJB1 Related Charcot-Marie-Tooth Disease with Deafness: X-Linked: PRPS1 Related Cholesteryl Ester Storage Disease Choreoacanthocytosis Choroideremia Chronic Granulomatous Disease: X-Linked Citrullinemia: Type I Classical Galactosemia Cohen Syndrome Combined Pituitary Hormone : PROP1 Related Congenital Disorder of Glycosylation: Type 1A: PMM2 Related Congenital Disorder of Glycosylation: Type 1B: MPI Related Congenital Disorder of Glycosylation: Type 1C: ALG6 Related Congenital Lipoid Adrenal Hyperplasia Congenital Neutropenia: Recessive Copper Transport Disorders Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Creatine Transporter Defect Crigler-Najjar Syndrome Cystic Fibrosis [ACOG/ACMG]* Cystinosis D-Bifunctional Protein Diabetes: Recessive Permanent Neonatal Dihydropyrimidine Dehydrogenase Du Pan Syndrome Dystrophic Epidermolysis Bullosa: Recessive Ehlers-Danlos Syndrome: Type VIIC Ellis-van Creveld Syndrome: EVC Related Ellis-van Creveld Syndrome: EVC2 Related Emery-Dreifuss Myopathy: X-Linked Enhanced S-Cone Ethylmalonic Aciduria Fabry s Disease Factor IX Factor VIII Familial Chloride Diarrhea Familial Dysautonomia [ACOG/ ACMG]* Familial Hyperinsulinism: Type 1: ABCC8 Related Familial Hyperinsulinism: Type 2: KCNJ11 Related Familial Mediterranean Fever Familial Mediterranean Fever: Mild Form Fanconi Anemia: Type A Fanconi Anemia: Type C [ACMG]* Fanconi Anemia: Type G Fanconi Anemia: Type J Fragile X Syndrome* Fumarase Galactokinase Gaucher Disease [ACMG]* Gitelman Syndrome Globoid Cell Leukodystrophy Glucose-6-Phosphate Dehydrogenase Glutaric Acidemia: Type I Glycine Encephalopathy: AMT Related Glycine Encephalopathy: GLDC Related Type IA Type IB Type II Type III Type IV Type V Type VII GM1-Gangliosidoses GRACILE Syndrome Guanidinoacetate Methyltransferase Hemochromatosis: Type 2A: HFE2 Related Hemochromatosis: Type 3: TFR2 Related Hemoglobinopathy: Hb C [ACOG]* Hemoglobinopathy: Hb D [ACOG]* Hemoglobinopathy: Hb E [ACOG]* Hemoglobinopathy: Hb O [ACOG]* Hereditary Fructose Intolerance Herlitz Junctional Epidermolysis Bullosa: LAMB3 Related

Hermansky-Pudlak Syndrome: Type 1 Hermansky-Pudlak Syndrome: Type 3 HMG-CoA Lyase Holocarboxylase Synthetase Homocystinuria Caused by CBS Hunter Syndrome Hurler Syndrome Hypohidrotic Ectodermal Dysplasia: X-Linked Hypophosphatasia Inclusion Body Myopathy: Type 2 Isovaleric Acidemia Joubert Syndrome Juvenile Retinoschisis: X-Linked Lamellar Ichthyosis: Type 1 Laryngoonychocutaneous Syndrome CEP290 Related GUCY2D Related LCA5 Related RDH12 Related Leigh Syndrome: French- Canadian Leydig Cell Hypoplasia Type 2A Type 2B Type 2C Type 2D Type 2E Type 2F Type 2I Lipoprotein Lipase Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Lysinuric Protein Intolerance Maple Syrup Urine Disease: Type 1A Maple Syrup Urine Disease: Type 1B Maple Syrup Urine Disease: Type 3 Meckel Syndrome: Type 1 Medium-Chain Acyl-CoA Dehydrogenase Metachromatic Leukodystrophy Methylmalonic Acidemia: MMAA Related Methylmalonic Acidemia: MMAB Related Methylmalonic Acidemia: MUT Related Methylmalonic Aciduria and Homocystinuria: Type cblc MTHFR : Severe Mucolipidosis: Type II/III Mucolipidosis: Type IV [ACMG]* Multiple Pterygium Syndrome Multiple Sulfatase Muscle-Eye-Brain Disease Myotubular Myopathy: X-Linked Navajo Neurohepatopathy Nemaline Myopathy: NEB Related Nephrotic Syndrome: Type 1 Nephrotic Syndrome: Type 2 CLN3 Related CLN5 Related CLN6 Related CLN8 Related MFSD8 Related PPT1 Related TPP1 Related Niemann-Pick Disease: Type A [ACMG]* Niemann-Pick Disease: Type B Niemann-Pick Disease: Type C1 Niemann-Pick Disease: Type C2 Nijmegen Breakage Syndrome Nonsyndromic Hearing Loss and Deafness: DFNB3 Related Nonsyndromic Hearing Loss and Deafness: GJB2 Related Oculocutaneous Albinism: Type 1 Oculocutaneous Albinism: Type 4 Omenn Syndrome Ornithine Transcarbamylase Ornithine Translocase Pendred Syndrome Persistent Mullerian Duct Syndrome: Type I Persistent Mullerian Duct Syndrome: Type II Phenylalanine Hydroxylase POLG Related Disorders: Autosomal Recessive Polyglandular Autoimmune Syndrome: Type 1 Primary Carnitine Primary Hyperoxaluria: Type 1 Primary Hyperoxaluria: Type 2 Primary Hyperoxaluria: Type 3 Progressive Familial Intrahepatic Cholestasis: Type 2 Propionic Acidemia: PCCA Related Propionic Acidemia: PCCB Related Pseudocholinesterase Pycnodysostosis Pyruvate Dehydrogenase : Autosomal Recessive Pyruvate Dehydrogenase : X-Linked Retinal Dystrophies: RLBP1 Related Retinitis Pigmentosa: Autosomal Recessive: DHDDS Related Rhizomelic Chondrodysplasia Punctata: Type 1 Salla Disease Sanfilippo Syndrome: Type A Sanfilippo Syndrome: Type B Sanfilippo Syndrome: Type C Sanfilippo Syndrome: Type D SCID: X-Linked Short-Chain Acyl-CoA Dehydrogenase Sickle-Cell Anemia [ACOG]* Sjogren-Larsson Syndrome Smith-Lemli-Opitz Syndrome Spinal Muscular Atrophy: SMN1 Related [ACMG]* Stargardt Disease Stuve-Wiedemann Syndrome Sulfate Transporter-Related Osteochondrodysplasia Tay-Sachs Disease [ACOG/ACMG]* Tyrosine Hydroxylase Tyrosinemia: Type I Usher Syndrome: Type 1B Usher Syndrome: Type 1C Usher Syndrome: Type 1D Usher Syndrome: Type 1F Usher Syndrome: Type 2A Usher Syndrome: Type 3 Very Long-Chain Acyl-CoA Dehydrogenase Walker-Warburg Syndrome Werner Syndrome Wilson Disease Wolcott-Rallison Syndrome PEX1 Related PEX2 Related PEX6 Related PEX10 Related

Chile Río refugio 9641 Pudahuel, Santiago +56 2 2935 3299 info@tag-genetics.com China 102#, 1009 Yishan Road Xuhui Districtl, Shangai +86 021 64956276 info@tag-genetics.cn México Av. Coyoacán #1622 Local 207, Colonia del Valle Delegación Benito Juarez D.F. +52 55 52003250 info@tag-genetics.com.mx www.taag-genetics.com